[EN] TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS<br/>[FR] TRIAZA-SPIRODÉCANONES UTILISÉES EN TANT QU'INHIBITEURS DE DDR1
申请人:HOFFMANN LA ROCHE
公开号:WO2017005583A1
公开(公告)日:2017-01-12
The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein L and R1 to R5 are as described herein, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.
[EN] KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES
申请人:TAKEDA PHARMACEUTICAL
公开号:WO2009129401A8
公开(公告)日:2009-12-17
Discovery of 2-(2-Chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2<i>H</i>-pyrazolo[3,4-<i>f</i>][1,4]oxazepin-8(5<i>H</i>)-one (PF-514273), a Novel, Bicyclic Lactam-Based Cannabinoid-1 Receptor Antagonist for the Treatment of Obesity
作者:Robert L. Dow、Philip A. Carpino、John R. Hadcock、Shawn C. Black、Philip A. Iredale、Paul DaSilva-Jardine、Steven R. Schneider、Ernest S. Paight、David A. Griffith、Dennis O. Scott、Rebecca E. O’Connor、Chudy I. Nduaka
DOI:10.1021/jm900255t
日期:2009.5.14
We report the design, synthesis, and structure-activity relationships of novel bicyclic lactam-based cannabinoid type 1 (CB,) receptor antagonists. Members of these series are potent, selective antagonists in in vitro/in vivo efficacy models of CB, antagonism and exhibit robust oral activity in rodent models of food intake. These efforts led to the identification of 19d, which has been advanced to human clinical trials for weight management.
N-fluoroalkyl-n-vinylalkanamides and preparation thereof
申请人:EASTMAN KODAK CO
公开号:US02585230A1
公开(公告)日:1952-02-12
Mechanism of hydrolysis of phosphorylethanolamine triesters. Multiple catalytic effects of an intramolecular amino group